Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785884 | 0.73 | — | — | |
| SCHEMBL18891103 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL1785556 | 0.70 | SMN1; SMN2 (0.42) | MEN1ALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL12607030 | 0.70 | IMPDH2 (0.30) | — | |
| SCHEMBL20504386 | 0.69 | GRIA2 (0.32) | MEN1ALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL12607027 | 0.69 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL18891004 | 0.69 | SMN1; SMN2 (0.41) | MEN1ALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL18190378 | 0.68 | NPC1 (0.33) | USP2 | |
| SCHEMBL1752520 | 0.68 | USP2 (0.40) | MEN1ALDH1A1KMT2APOLBUSP2 | |
| SCHEMBL1783961 | 0.67 | HTT (0.36) | MEN1ALDH1A1KMT2ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320216-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-10-16 | — | — | US | disclosed |
| US-12351585-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2025-07-08 | — | — | US | disclosed |
| US-20240343730-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-17 | — | — | US | disclosed |
| US-11897890-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-13 | — | — | US | disclosed |
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-3377495-B1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1-F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| US-11242347-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2022-02-08 | — | — | US | disclosed |
| CN-108290896-B | 2-phenyl-3, 4-dihydropyrrolo [2,1-F ] [1,2,4] triazinone derivatives and uses thereof | 托帕杜制药公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200239478-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10570137-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2020-02-25 | — | — | US | disclosed |
| US-20180312513-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2018-11-01 | — | — | US | disclosed |
| EP-3377495-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F][1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2018-09-26 | — | — | EP | disclosed |
| US-8273901-B2 | Process of forming a pyrrole compound | Nanyang Technical University (SG) | 2012-09-25 | — | — | US | disclosed |
| US-20110124881-A1 | PROCESS OF FORMING A PYRROLE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124881-A1 | PROCESS OF FORMING A PYRROLE COMPOUND | OXER1, OGDH, OPRD1 | MEN1 4754/4885ALDH1A1 67/4885KMT2A 1604/4885 |
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, GNAO1, PDE3A | MEN1 2414/4885ALDH1A1 759/4885KMT2A 3833/4885 |
| US-11242347-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, PDE3A, CHRM3 | MEN1 3048/4885ALDH1A1 809/4885KMT2A 4114/4885 |
| US-20240343730-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, GNAO1 | MEN1 2320/4885ALDH1A1 623/4885KMT2A 3847/4885 |
| US-20250320216-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, PDE3B | MEN1 2053/4885ALDH1A1 702/4885KMT2A 4063/4885 |
| US-20180312513-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, GNAO1, PDE3A | MEN1 2414/4885ALDH1A1 759/4885KMT2A 3833/4885 |
| US-10570137-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | MEN1 2414/4885ALDH1A1 759/4885KMT2A 3833/4885 |
| US-20200239478-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, GNAO1, PDE3A | MEN1 2414/4885ALDH1A1 759/4885KMT2A 3833/4885 |
| US-11897890-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | MEN1 2414/4885ALDH1A1 759/4885KMT2A 3833/4885 |
| US-12351585-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, PDE3A, GNAO1 | MEN1 2320/4885ALDH1A1 623/4885KMT2A 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.